Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo
Open accessThe DOI matches its Crossref record.
Abstract
Immune suppression in tumor-bearing hosts is considered to be one factor causally associated with the growth of antigenic tumors. Support for this hypothesis has come from reports that spleen T cells in tumor-bearing mice are deficient in either priming or effector phase functions. We have reexamined this hypothesis in detail using multiple murine tumor models, including transplantable adenocarcinoma, melanoma, sarcoma, and thymoma, and also a transgenic model of spontaneous breast carcinoma. In both in vitro and in vivo assays of T cell function (proliferation, cytokine production, induction of CD8+ alloreactive CTL, and development of anti-keyhole limpet hemocyanin CD4+ T cells, rejection of allogeneic or syngeneic regressor tumors, respectively) we show that mice bearing sizable tumor burdens are not systemically suppressed and do not have diminished T cell functions. Therefore, if immune suppression is a causal function in the growth of antigenic tumor, the basis for escape from immune destruction is likely to be dependent upon tumor-induced T cell dysfunction at the site of tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
Cham, C. M., Driessens, G., O'Keefe, J. P., & Gajewski, T. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200838289 · Cited by 388
“Dysfunctional tumor-infiltrating lymphocytes can usually recover effector functions after culture ex vivo [27], which is always performed in standard culture medium rich in glucose.”
BackgroundDanna, E. A., Sinha, P., Gilbert, M., Clements, V. K., Pulaski, B. A., & Ostrand-Rosenberg, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2646 · Cited by 371
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
Derangement of immune responses by myeloid suppressor cells
Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., Zanovello, P., & Bronte, V. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0443-2 · Cited by 335
Xu, Z., Chen, Y., Ma, L., Chen, Y., Liu, J., Guo, Y., Yu, T., Zhang, L., Zhu, L., & Shu, Y. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.046 · Cited by 319
T cell anergy and costimulation
Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 305
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells
Bronte, V., Serafini, P., Apolloni, E., & Zanovello, P. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200111000-00001 · Cited by 250
“The choice of the immunologic assay might thus explain some discrepancies found in the degree of functional impairment in different mouse tumor models, which may occasionally lead to the conclusion that late-stage tumors are not associated with impaired systemic T-cell responses (104).”
ResultSaio, M., Radoja, S., Marino, M., & Frey, A. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5583 · Cited by 157
Self-citationTGF-beta: a master switch in tumor immunity
Gigante, M., Gesualdo, L., & Ranieri, E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802430378 · Cited by 45
Metadata
- Authors
- Radoja, S., Rao, T. D., Hillman, D., & Frey, A. B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03-01
- Volume
- 164
- Issue
- 5
- Pages
- 2619-2628
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1625062092
- Cited by
- 88
- References
- 0
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.